Objectives: Although mitral valve (MV) repair is known to be superior to replacement in overall clinical outcomes, the appropriateness of valve repair for rheumatic MV disease remains controversial because of the risks of recurrent mitral dysfunction and the need for re-operation. Methods: From 1997 to 2007, 540 patients underwent either isolated MV repair (n = 122) or replacement with a mechanical prosthesis (n = 418) in treatment of rheumatic MV disease. Survival and morbidity were evaluated using Kaplan-Meier analysis and Cox regression, including propensity score analysis. Results: Follow-up was complete in 96.1% of patients (mean, 71.8 AE 39.1 months). Patients undergoing repair were younger; more likely to have predominant mitral regurgitation; and less likely to show atrial fibrillation (AF), significant tricuspid regurgitation or pulmonary hypertension, than those undergoing replacement. The 10-year freedom from cardiac death rate was 92.0 AE 4.2% following repair and 86.8 AE 2.3% following replacement (P = 0.042). After adjustment for baseline differences, repair and replacement were found to be similar in terms of cardiac survival (P = 0.25), re-operation (P = 0.68) and thrombo-embolic complication (P = 0.20) rates. Replacement patients had more anticoagulation therapy-related complications (P = 0.030). Independent factors positively associated with combined cardiac death and major morbidities included older patient age (P = 0.010), uncorrected AF (P = 0.015) and the presence of significant tricuspid regurgitation (P = 0.012) or coronary disease (P = 0.043). The influence of the type of MV surgery was statistically marginal (P = 0.093). Conclusions: When performed for selected patients, MV repair had excellent durability comparable to mechanical valve replacement in rheumatic disease. Both MV repair and replacement had comparable long-term clinical results; therefore, repair surgery seems to be more beneficial by avoiding troublesome life-long anticoagulation and risks of bleeding. #
Introduction
Mitral valve (MV) repair is known to be superior to replacement in terms of operative mortality, functional outcomes and long-term survival in degenerative MV disease [1, 2] . A further advantage of MV repair over mechanical valve replacement is avoidance of complications related to lifelong anticoagulation therapy or systemic thrombo-embolism. Therefore, MV repair is regarded as the procedure of choice in patients with mitral regurgitation (MR) caused by nonrheumatic MV disease [3, 4] .
In contrast to non-rheumatic MV disease patients, there is a continuing debate regarding the use of valve repair in rheumatic MV disease patients [5, 6] . It may be that disease progression in such patients necessitates MV replacement in the long term, making repair surgery redundant despite its advantages. However, the currently available clinical data do not assist in resolving this issue.
The present study investigated whether MV repair or replacement was more appropriate for treatment of rheumatic mitral disease patients. The study compared long-term clinical outcomes following repair or replacement. We used propensity score analysis to adjust for differences in the baseline characteristics to reduce the effect of treatment selection bias and potential confounding.
Materials and methods

Patients
From July 1997 to July 2007, 1300 patients underwent MV surgery for rheumatic mitral disease at the Asan Medical Center, Seoul, Korea. Patients who underwent minimally invasive robotic surgery or concomitant cardiac surgery for congenital heart defects, aortic valve, aorta, cardiac tumour, pericardial diseases or coronary artery bypass grafting were excluded to reduce heterogeneity in the patient population. Patients with a history of previous cardiac surgery were also excluded. However, patients who had an incidental coronary lesion including a requirement for coronary artery bypassing (i.e., single-vessel disease) or had undergone concomitant repair for tricuspid regurgitation were not excluded. Because the primary objective of the study was to compare the longterm durability of MV repair with replacement, as well as thrombo-embolic or bleeding complications, patients with tissue valve implants (n = 112) were also excluded to form two distinct patient groups. Finally, a total of 540 patients met the necessary criteria. Patients were divided into two groups for analysis -repair (MV repair, n = 122) and replacement (MV replacement with mechanical prosthesis, n = 418).
This study was approved by our institution ethics committee/institutional review board.
Echocardiography
Two-dimensional echocardiography and Doppler colour flow imaging were performed on all patients using a HewlettPackard Sonos 2500 or 5500 imaging system equipped with a 2.5-MHz transducer (Hewlett-Packard, Andover, MA, USA). Preoperative echocardiography was performed in all patients within 2 months before surgery. The end-systolic and enddiastolic dimensions of the left ventricle (LV) were measured from parasternal M-mode acquisitions, and end-systolic volume, end-diastolic volume and ejection fraction of the LV were calculated using the biplane Simpson method. With the simplified proximal isovelocity surface area (PISA) method, the degree of MR was graded as mild (PISA radius <4 mm), moderate (PISA radius 4-8 mm) or severe (PISA radius >8 mm). MV area was estimated using the pressure half-time method. Left atrial (LA) size was measured by its antero-posterior diameter on parasternal long-axis view at end systole. Pulmonary artery systolic pressures were estimated using continuous-wave Doppler and the simplified Bernoulli equation (4Â [peak velocity of tricuspid regurgitation] 2 ), with 5 mmHg added for the estimated right atrial pressure [7] . Significant pulmonary hypertension was defined as a tricuspid regurgitation peak velocity >3.4 m s À1 , equal to a pulmonary artery pressure >50 mmHg.
Surgical procedures
A median sternotomy approach and conventional ascending aorta and bicaval cannulation were used for all patients. A longitudinal right-sided left atriotomy was the conventional approach. Moderately hypothermic (28-32 8C) cardiopulmonary bypass was used, and myocardial protection was achieved with cold or tepid blood cardioplegia.
Exclusion criteria for repair were severe leaflet calcification or extensive subvalvular fusion or annular extension. Although severe mitral stenosis (MS) was not an exclusion criterion for repair, valvuloplasty was generally avoided in patients with an MV area <1.0 cm 2 . Consequently, an MV area <1.0 cm 2 was present in 10 repair patients (8.2%) and 186 replacement patients (44.5%) (P < 0.001).
Details of the MV repair techniques are summarised in Table 1 . Patients in whom the papillary muscles were fused, but not involving the free margin of the valve leaflets, papillary muscle splitting was done. However, if papillary muscles were fused directly to the free margin, valve replacement was done rather than repair. MR caused by chordae elongation especially at anterior leaflet was managed with new chordae formation technique. In cases where leaflet mobilisation was not enough to compensate tissue retraction, leaflet extension or augmentation techniques were adopted. With these techniques, the anterior leaflet mobility and the surface of leaflet coaptation were increased allowing the insertion of a larger annuloplasty ring, thereby reducing the risk for stenosis [8] .
All replacement group patients received a bi-leaflet mechanical valve. Surgeons attempted to retain subvalvular tissue whenever possible in valve replacement: redundant tissue was imbricated, excessive cuspal tissue was sliced and the calcific nodules were excised.
Seventy-nine repair group (88.8%) and 116 replacement group (33.6%) patients underwent a concomitant maze procedure. The maze procedure was performed using a modified Coz-Maze III technique, the details of which have been described previously [9, 10] . In summary, LA tissue incorporation upon the pulmonary vein isolation procedure was minimised by tightly encircling the pulmonary vein orifices, and the 'cut and sew' technique was replaced with ablation using either cryothermia (n = 185) or microwave (n = 10). Ablation of the right atrial cavo-tricuspid isthmus was performed to prevent postoperative atrial flutter.
Intra-operative trans-oesophageal echocardiography was routinely used.
Follow-up
Data were obtained up to April 2009 and were collected during annual visits to the outpatient clinic or by telephone interviews. Operative mortality was defined as death within 30 days of surgery or in-hospital death. Deaths were classified as cardiac or non-cardiac on the basis of medical records. All deaths were considered of cardiac origin unless a non-cardiac origin was established clinically or at autopsy. The end point of the study was defined as the composite of operative mortality, cardiac death and valve-related complications. Valve-related complications included thromboembolic events, infective endocarditis, bleeding complications secondary to anticoagulation or the need for reoperation during follow-up. Bleeding secondary to anticoagulation was defined as any requirement for transfusion, unplanned hospital admission or a haemostatic intervention.
Postoperative management
The repair group patients who underwent annuloplasty ring implantation were routinely administered warfarin for anticoagulation for 3-6 months postoperatively, with a target international normalised ratio (INR) of 1.5-2.5. The maintenance of anticoagulation therapy thereafter was according to the thrombo-embolism risk and cardiac rhythm status determined for each patient individually. Thirty-one patients in the repair group received anticoagulation therapy beyond 6 months postoperatively. The indications for the long-term anticoagulation in the repair group were presence of atrial fibrillation (AF) with or without other risk factors in 19 patients, re-oparative MV replacement in three, MV or tricuspid valve dysfunction in seven, congestive heart failure without significant valvulopathy in one and history of stroke in one. The target INR for the replacement group was 2.0-3.0. The adequacy of anticoagulation therapy was monitored and adjusted at 3-monthly outpatient visits.
Statistics
Data are presented as frequencies, or means with standard deviations. Comparisons of patient characteristics between groups were performed using the chi-square or Fisher's exact tests for categorical variables and Student's unpaired t-test for continuous variables.
Kaplan-Meier curves were employed to delineate freedom from death or major adverse events. Stratified survival curves were plotted to explore unadjusted differences for variables of interest (log-rank test). For multivariate analyses, Cox proportional hazards model was used to examine the association of baseline characteristics with time to death or major events. Variables with a probability value 0.20 in univariate analyses were candidates for the multivariate Cox proportional hazards model.
To reduce the effect of treatment selection bias and potential confounding, we performed an adjustment for the differences in the baseline characteristics using a propensity score analysis. The propensity scores were estimated using multiple logistic regression analysis without regard to outcome variables. Pre-specified covariates (Table 1) were included in the full non-parsimonious models for the repair group versus the replacement group. This score ranged from 0.047 to 0.999 and, in effect, represented the probability that a patient would be assigned to the replacement group. The model was well-calibrated (Hosmer-Lemeshow test: P = 0.81) with excellent discrimination (C statistic = 0.90). There was limited overlap between propensity scores in both the groups, and therefore it was used as a covariate in statistical models. Cox regression analyses were then repeated, with the inclusion of the propensity score as a potential predictor of late outcomes. The propensity score did not emerge as an independent predictor of any late outcomes, suggesting that differences attributed to the type of valve surgery by the initial Cox regression analyses were not explained by surgical bias in patient selection on the basis of their preoperative characteristics. Results were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs).
A P value 0.05 was considered to indicate significance. SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
Results
Baseline characteristics
The mean age at surgery was 48.9 AE 11.5 years, and 356 patients (65.9%) were female. Clinical follow-up was complete in 96.1% of patients, with a mean follow-up duration of 71.8 AE 39.1 months.
The repair group patients were younger, biased towards the female gender and were more likely to have predominant MR than were replacement group patients. The replacement group patients were more likely to have significant tricuspid regurgitation and pulmonary hypertension than were the repair group patients. Although AF was more frequently found in the replacement group, a greater proportion of AF patients in the repair group underwent the concomitant maze procedure than in the replacement group (Table 2) .
Early outcomes
There were six early deaths (1.1%, two repair group and four replacement patients; P = 0.53). The causes of early death were cardiac arrest in two, cerebrovascular attack in one, gastrointestinal bleeding during intravenous heparin infusion in one and sudden death in two patients. There were 44 cases of early postoperative complications without significant inter-group differences in rate (Table 3) .
Overall survival and freedom from cardiac death
There were 55 late deaths including 41 cardiac deaths. Non-cardiac causes of death were malignancy in nine, underlying end-stage renal disease in two, underlying pulmonary disease in two and meningitis in one patient. The overall 5-and 10-year survival rates were 95.0 AE 1.9% and 86.1 AE 4.9% in the repair group, and 91.8 AE 1.4% and 84.5 AE 2.3% in the replacement group, respectively (P = 0.19). The repair group showed better freedom from cardiac death outcome than did the replacement group (Fig. 1) . Univariate analysis identified MV replacement, older patient age (>50 years), diabetes and significant tricuspid regurgitation or pulmonary hypertension as risk factors for cardiac death. Multivariate analysis found that older patient age (>50 years), diabetes and significant pulmonary hypertension were independent risk factors for cardiac death (Table 4) .
Thrombo-embolic complications
There were 22 thrombo-embolic complications, including 20 strokes and two peripheral-artery embolic occlusions (one femoral and one popliteal artery). The 5-and 10-year freedoms from thrombo-embolic complication rates were 98.2 AE 1.2% and 96.5 AE 2.0% in the repair group, and 96.2 AE 1.0% and 91.5 AE 2.4% in the replacement group, respectively (P = 0.20). Although preoperative rhythm status (AF vs normal sinus rhythm) did not affect the postoperative thrombo-embolic complication rate (P = 0.48), univariate analysis showed that not performing the maze procedure in preoperative AF patients was the only factor associated with a higher rate of thrombo-embolic events (P = 0.038). However, multivariate analysis did not identify non-performance of the maze procedure as an independent risk factor for thrombo-embolic events (HR 2.20, 95% C.I.: 0.68-7.16; P = 0.19).
Re-operation
Three repair group and 11 replacement group patients underwent re-operations during follow-up. In all repair group cases, the indication for re-operation was recurrent MR. In the Abbreviations: SSS, sick sinus syndrome. replacement group, the indications were LV rupture in one, prosthetic valve malfunction in three, valve thrombosis in two, infective endocarditis in two, paravalvular leakage in one and progression of tricuspid regurgitation in two patients. The 10-year freedom from re-operation rates were 97.0 AE 1.6% in the repair group and 94.2 AE 0.2% in the replacement group (P = 0.68). Univariate and multivariate analyses revealed that the presence of significant preoperative pulmonary hypertension was the only independent risk factor for re-operation (HR 3.75, 95% C.I.: 1.21-11.57; P = 0.022).
Infective endocarditis and anticoagulation-related complications
There were only two cases of infective endocarditis, both in the replacement group. Ten patients were re-admitted for management of congestive heart failure (one repair and nine replacement group patients). Three repair group patients (2.4%) and 30 replacement group patients (7.2%) experienced major complications secondary to anticoagulation therapy. The 10-year freedom from anticoagulation-related complications was 97.3 AE 1.4 in the repair group and 89.6 AE 0.2% in the replacement group (P = 0.030).
The repair group was superior to the replacement group in terms of freedom from cardiac death and major adverse events ( Fig. 2(a) ). Univariate analysis showed that the type of MV surgery, patient age, presence of coronary lesion, not performing the maze procedure in the presence of AF (Fig. 2(b) ) and significant tricuspid regurgitation or pulmonary hypertension were associated with cardiac death and major adverse events. Multivariate analysis showed that older patient age, not performing the maze procedure in the presence of AF and presence of significant tricuspid regurgitation or coronary disease were independent risk factors for cardiac death and major adverse events ( Table 5 ). The influence of the type of MV surgery was statistically marginal (P = 0.093). Abbreviations: LV, left ventricle; *P < 0.05. Abbreviations: LV, left ventricle; *P < 0.05.
Echocardiographic assessment for repair durability
Of the 120 early survivors in the repair group, 115 (95.8%) were evaluated with echocardiography beyond 6 months postoperatively. During a mean echocardiography follow-up duration of 66.0 AE 38.6 months, 20 patients (16.7%) showed significant MR (>grade 2; n = 16) or moderate MS (mitral valve area of 1.2-1.4 cm 2 ; n = 4), but no severe MS (mitral valve area <1.0 cm 2 ). Three MR patients underwent reoperative mitral replacement. Of the other significant MR patients (n = 13), four patients were fitted to the surgical indication according to the current American College of Cardiology/American Heart Association guidelines, whereas another nine patients were free of symptoms or LV dysfunction defined as LV ejection fraction of less than 60% or LV systolic dimension of greater than 40 mm [11] .
Discussion
The present study found that MV repair and MV replacement for rheumatic MV disease resulted in similar outcomes in terms of operative mortality and morbidity, long-term survival and late valve-related complications. With regard to the durability of the procedure, MV repair was comparable to replacement as evidenced by similar re-operation rates. Adjusted multivariate analysis revealed that older patient age, the presence of significant preoperative tricuspid regurgitation (>grade 2) or coronary disease and not performing the maze procedure in the presence of AF, all correlated with poor event-free survival.
MV repair is well recognised as the procedure of choice for patients with degenerative MR. Repair is associated with low operative mortality and morbidity, better haemodynamic characteristics, better preservation of LV function, improved late survival and a lower likelihood of valve-related complications, compared with replacement [2, 12] . However, valve repair in rheumatic MV disease patients remains controversial because several studies have demonstrated inferior durability of reconstruction in rheumatic patients [6, 13, 14] . Most previous studies on rheumatic MV repair, however, appear to have focussed on younger patients [13, 15] or were related to recurrent episodes of rheumatic inflammation [16] . A study that did examine long-term results after MV repair in rheumatic disease lacked an adequate control group [15] .
Yau and colleagues compared MV repair with replacement in rheumatic MV disease patients [14] . The cited authors found that valve replacement with a mechanical prosthesis resulted in a lower re-operation rate but poorer long-term survival and a higher incidence of thrombo-embolic complications. Consequently, the authors concluded that rheumatic MVs should be repaired when technically feasible, accepting the risk of re-operation, to maximise survival and reduce morbidity. However, the cited study included data from surgery performed in the 1970s, and much progress has since been made in the field of cardiac valve replacement surgery, such as the introduction of bi-leaflet mechanical valves [17, 18] and the concept of subvalvular apparatus preservation [19, 20] . MV repair techniques have also evolved, and operative outcomes have improved. Therefore, repair versus replacement for rheumatic mitral disease needs to be reexamined in the current era.
A recent study examined a homogeneous population of rheumatic mitral disease patients who underwent isolated MV surgery [21] . The cited study, involving 33 repair and 59 replacement patients, found that the groups had similar operative mortality and morbidity rates. During a mean follow-up time of approximately 3 years, the repair group enjoyed better survival than did the replacement group. However, multivariate analysis did not find that the type of MV surgery was independently associated with late deaths. Both groups had similar major adverse cardiac event-free survival rates. The authors concluded that rheumatic mitral valves should be repaired in selected patients with appropriate valvular pathology. However, the cited study contained only a small number of patients, the follow-up period was short, and the follow-up rate (81.5%) low.
The present study had a large patient population, a long follow-up duration and low follow-up loss (3.9%) than the previous studies. To reduce the impact of treatment selection bias, we adjusted for significant differences in baseline patient characteristics using the propensity scoreadjusted Cox proportional hazards regression model.
The current study included the maze procedure as a candidate risk variable in multivariable analysis, in addition to the presence of AF. The prevalence of sinus rhythm was 85.7% at 5 years in patients who underwent the maze procedure, and only 23.5% in patients who did not undergo the procedure in the presence of AF. The maze procedure was associated with better event-free survival. This is probably attributable to the combined effect of a modest reduction in thrombo-embolic complications (P = 0.038) and less requirement for anticoagulation therapy by achieving sinus rhythm in the repair group, which resulted in a lower incidence of bleeding complications.
Even though we observed an apparent trend in favour of repair over replacement in terms of thrombo-embolic complications, the difference did not reach statistical significance (P = 0.20). However, we believe this difference would become significant with evaluation of more patients and a longer follow-up duration. The good thrombo-embolic complication outcomes observed in the replacement group possibly reflected the strict anticoagulation protocol used in our institution. Patients with a target value INR level (2-3) attended the outpatient clinic at 3-month intervals, whereas patients with inadequate INR values attended weekly or monthly until the target INR value was achieved. Furthermore, a concomitant maze procedure might have had a positive effect on thrombo-embolism prevention in the replacement group. Even in mechanical MV replacement patients, addition of the maze procedure is reported to further decrease the risk of late thrombo-embolic complications in the presence of AF [22, 23] . One group reported that not performing the maze procedure was the only risk factor for late stroke, and recommended adding the maze procedure in mechanical MV replacement patients [22] . Similarly, another study found that cerebrovascular accident (CVA) risk remained high in MV replacement patients on anticoagulation therapy, and that the risk was reduced when sinus rhythm was restored [23] .
The repair group was younger than the replacement group, consistent with the findings that use of mitral repair is inversely correlated with age [6, 14, 21] . Acute rheumatic mitral disease is characterised by chordal elongation, leaflet prolapse, annular dilatation and consequent predominant MR in younger individuals. As inflammation and scarring progresses with time, MS becomes more predominant in older rheumatic mitral patients [24] . As a consequence, the number of pure MR cases declines with increasing age. This ongoing activity and complicated valvular pathology may make mitral repair more difficult, and associated with less favourable postoperative outcomes [21, 24] . Age-related differences in rheumatic pathologies were observed in the present work and are commonly reported in other rheumatic mitral disease studies [21, 25] . Besides complicated valvular pathology, other preoperative findings such as the presence of AF, significant tricuspid regurgitation or pulmonary hypertension also demonstrate that chronic and advanced rheumatic mitral diseases were more frequently found in the replacement patients in the present study.
Although this study showed excellent repair durability in terms of re-operation, significant remnant or recurred MV diseases were observed in 20 patients through a long-term echocardiographic follow-up. Three patients underwent reoperation, another four patients were already fitted to the surgical indication and 16 patients were free of symptoms or LV dysfunction. The latter patients group, who may currently be suitable for medical management, should be closely monitored for any clinical deterioration and be managed accordingly.
Limitation
This study was subject to the limitations inherent in retrospective observational data studies. The non-randomised design may have affected the results because of the presence of unmeasured confounders, procedure bias or detection bias, despite the use of statistical adjustments. The decision to perform an MV repair or replacement was at the attending surgeon's discretion; some authors in this study have been prudent to perform an MV repair in rheumatic disease because of concerns about disease recurrence and reoperation. The more prudent patient selection in rheumatic disease may have resulted in the tendency towards performing the MV replacement than repair although some surgeons had more aggressive approach for MV repair in our institution.
Conclusion
When performed for selected patients, MV repair had excellent durability comparable to mechanical valve replacement in rheumatic disease. MV repair and replacement had comparable long-term clinical results. Therefore, repair would appear to be more beneficial than replacement as this avoids the need for lifelong anticoagulation therapy and the associated risks of bleeding.
